Inner Cosmos is a neurotechnology company developing an implantable neuromodulation platform designed to treat major depressive disorder through targeted brain stimulation. The company’s approach centers on a minimally invasive implant that delivers low-dose electrical stimulation to specific cortical regions implicated in mood regulation.

The system combines a small, implantable neural device with external software that enables programmable stimulation protocols and longitudinal monitoring. By focusing on precision targeting and low-energy stimulation, the platform aims to modulate dysfunctional neural circuits while minimizing side effects associated with broader neuromodulation approaches.

Inner Cosmos’s technology is being advanced for clinical evaluation in depression and related mood disorders. The company positions its platform as an experimental, next-generation alternative to existing neuromodulation therapies, sitting at the intersection of implantable neurotechnology and digital therapeutics.